Kentucky Retirement Systems Insurance Trust Fund Boosts Position in Boston Scientific Co. (NYSE:BSX)

Kentucky Retirement Systems Insurance Trust Fund boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,284 shares of the medical equipment provider's stock after purchasing an additional 3,683 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund's holdings in Boston Scientific were worth $4,223,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. TFC Financial Management Inc. boosted its position in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 210 shares in the last quarter. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth about $29,000. Dunhill Financial LLC boosted its position in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 152 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at about $28,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.93 during trading hours on Friday, reaching $104.44. 5,512,880 shares of the company's stock were exchanged, compared to its average volume of 6,033,932. Boston Scientific Co. has a 1 year low of $65.52 and a 1 year high of $107.17. The company has a market cap of $154.12 billion, a P/E ratio of 83.55, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company's 50 day moving average is $97.98 and its two-hundred day moving average is $89.27. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the sale, the chief financial officer now directly owns 241,451 shares of the company's stock, valued at $25,369,256.57. This trade represents a 5.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 153,640 shares of company stock valued at $15,718,289 in the last ninety days. Corporate insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Barclays upped their target price on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Citigroup upped their target price on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research report on Thursday, February 6th. TD Cowen upped their target price on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. Finally, Piper Sandler upped their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.